XML 20 R8.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Retained earnings
Accumulated other comprehensive loss
Beginning balance (in shares) at Dec. 31, 2023   46,078,464      
Beginning balance at Dec. 31, 2023 $ 1,892,998 $ 461 $ 472,201 $ 1,491,956 $ (71,620)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net (loss) income (1,040)     (1,040)  
Other comprehensive (loss) income, net of tax expense 8,151       8,151
Issuance of restricted stock, net (in shares)   69,795      
Issuance of restricted stock, net (3,948)   (5,450) 1,502  
Repurchase and retirement of common stock (in shares)   (3,500,000)      
Repurchase and retirement of common stock (181,830) $ (35) (24,973) (156,822)  
Share-based compensation 30,633   30,633    
Issuance of shares under employee stock purchase plan (in shares)   92,589      
Issuance of shares under employee stock purchase plan 4,525 $ 1 4,524    
Increase in fair value of conversion feature on 3.625% Convertible Notes, net of tax effect of $1,000 3,001   3,001    
Other, net (178)   335 (513)  
Ending balance (in shares) at Sep. 30, 2024   42,740,848      
Ending balance at Sep. 30, 2024 1,752,312 $ 427 480,271 1,335,083 (63,469)
Beginning balance (in shares) at Jun. 30, 2024   44,740,322      
Beginning balance at Jun. 30, 2024 1,869,887 $ 447 476,232 1,471,543 (78,335)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net (loss) income (48,577)     (48,577)  
Other comprehensive (loss) income, net of tax expense 14,866       14,866
Issuance of restricted stock, net (in shares)   526      
Issuance of restricted stock, net (110)   (198) 88  
Repurchase and retirement of common stock (in shares)   (2,000,000)      
Repurchase and retirement of common stock (96,920) $ (20) (9,250) (87,650)  
Share-based compensation 10,161   10,161    
Increase in fair value of conversion feature on 3.625% Convertible Notes, net of tax effect of $1,000 3,001   3,001    
Other, net 4   325 (321)  
Ending balance (in shares) at Sep. 30, 2024   42,740,848      
Ending balance at Sep. 30, 2024 $ 1,752,312 $ 427 480,271 1,335,083 (63,469)
Beginning balance (in shares) at Dec. 31, 2024 42,848,339 42,848,339      
Beginning balance at Dec. 31, 2024 $ 1,810,882 $ 428 491,891 1,401,034 (82,471)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net (loss) income 46,984     46,984  
Other comprehensive (loss) income, net of tax expense 23,697       23,697
Issuance of restricted stock, net (in shares)   165,479      
Issuance of restricted stock, net (4,452) $ 3 (8,110) 3,655  
Repurchase and retirement of common stock (in shares) [1]   (3,154,566)      
Repurchase and retirement of common stock [1] (115,454) $ (32) (38,457) (76,965)  
Share-based compensation 33,591   33,591    
Issuance of shares under employee stock purchase plan (in shares)   133,956      
Issuance of shares under employee stock purchase plan 3,750 $ 1 3,749    
Other, net $ (89)   3 (92)  
Ending balance (in shares) at Sep. 30, 2025 39,993,208 39,993,208      
Ending balance at Sep. 30, 2025 $ 1,798,909 $ 400 482,667 1,374,616 (58,774)
Beginning balance (in shares) at Jun. 30, 2025   41,168,057      
Beginning balance at Jun. 30, 2025 1,842,659 $ 412 484,498 1,409,468 (51,719)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net (loss) income (3,598)     (3,598)  
Other comprehensive (loss) income, net of tax expense (7,055)       (7,055)
Issuance of restricted stock, net (in shares)   1,710      
Issuance of restricted stock, net (29)   (62) 33  
Repurchase and retirement of common stock (in shares)   (1,176,559)      
Repurchase and retirement of common stock (44,882) $ (12) (13,874) (30,996)  
Share-based compensation 12,111   12,111    
Other, net $ (297)   (6) (291)  
Ending balance (in shares) at Sep. 30, 2025 39,993,208 39,993,208      
Ending balance at Sep. 30, 2025 $ 1,798,909 $ 400 $ 482,667 $ 1,374,616 $ (58,774)
[1] Includes 143,161 shares received in connection with sale of our minority equity ownership interest in OpenEvidence during the nine months ended September 30, 2025.